Previous Article | Next Article ![]()
Applied and Environmental Microbiology, February 2007, p. 1107-1113, Vol. 73, No. 4
0099-2240/07/$08.00+0 doi:10.1128/AEM.02265-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Department of Microbiology and Immunology, University of Otago, P.O. Box 56, Dunedin, New Zealand,1 BLIS Technologies Ltd., Centre for Innovation, P.O. Box 56, Dunedin, New Zealand,2 Manchester Medical Microbiology Partnership, University of Manchester School of Medicine, Manchester M13 9WL, United Kingdom3
Received 26 September 2006/ Accepted 17 December 2006
The commercial probiotic Streptococcus salivarius strain K12 is the prototype of those S. salivarius strains that are the most strongly inhibitory in a standardized test of streptococcal bacteriocin production and has been shown to produce the 2,368-Da salivaricin A2 (SalA2) and the 2,740-Da salivaricin B (SboB) lantibiotics. The previously uncharacterized SboB belongs to the type AII class of lantibiotic bacteriocins and is encoded by an eight-gene cluster. The genetic loci encoding SalA2 and SboB in strain K12 have been fully characterized and are localized to nearly adjacent sites on pSsal-K12, a 190-kb megaplasmid. Of 61 strongly inhibitory strains of S. salivarius, 19 (31%) were positive for the sboB structural gene. All but one (strain NR) of these 19 strains were also positive for salA2, and in each of these cases of double positivity, the two loci were separated by fewer than 10 kb. This is the first report of a single streptococcus strain producing two distinct lantibiotics.
Published ahead of print on 28 December 2006.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»